RAPP

$27.89+0.27 (+0.98%)

Market OpenAs of Mar 17, 4:51 PM UTC

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$27.89
Potential Upside
5%
Whystock Fair Value$29.28
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The comp...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-28.22%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
25.75

Recent News

Motley Fool
Mar 16, 2026

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 16, 2026

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 16, 2026

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 18, 2026

We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. Indeed, Rapport Therapeutics...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 9, 2026

Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff?

Rapport Therapeutics announced in early January 2026 that the FDA has cleared RAP-219 to move into Phase 3 registrational trials for focal onset seizures, while the company advances a broader neuroscience pipeline spanning epilepsy, bipolar mania, chronic pain and migraine. A key nuance is that, even as the FDA lifted a clinical hold on Rapport’s diabetic peripheral neuropathic pain program, the company is directing resources toward its α6β4 pain franchise and epilepsy portfolio,...

BEARISH
Negative press. News cycle fixated on risk factors or misses.